University of California Berkeley, University of California San Francisco and Seattle-based University of Washington launched a collaborative research network that will use artificial intelligence, data analytics and other health technologies to advance treatments for brain and nervous system diseases, according to…
Innovation
Boston-based Baystate Health launched new efforts to develop artificial intelligence tools that will help advance innovations in radiology, neurology and oncology, according to a Nov. 12 news release.
Although healthcare is being flooded with artificial intelligence, data analytics and a slew of apps, it is unclear whether these solutions will solve healthcare challenges. One of the reasons is because clinicians are not always involved in the innovation processes,…
As the use of air ambulances declined from 2008-17, the cost of an air ambulance trip more than doubled, according to a Health Care Cost Institute analysis published Nov. 7.
John Pigott, MD, is chief innovations officer and leads strategic business development for Toledo, Ohio-based ProMedica and its innovation arm.
Constant, continuous innovation is crucial to improving healthcare, whether through the introduction of new technologies and treatments or by challenging popular beliefs and traditions, according to microbiologist Peter Piot, MD, PhD.
The years-long gap between developing the technology to improve a product, service or process and actually implementing the technology and reaping the benefits is "one of the great puzzles of our age," according to Malcolm Gladwell.
While other industries' innovation efforts center on increasing consumers' mobile access to services or speeding delivery of those services, the goal in healthcare skews toward personalized, lower-cost services and products, a new report suggests.
The most truly innovative companies place a higher priority on risk, exploration and breakthrough ideas than their less successful peers, and pursue their lofty goals with a reliance on data analytics and executive backing, among other shared qualities.
PathAI, a developer of artificial intelligence technology for use in pathology research, closed its Series B investment round Nov. 4, including participation from the Merck Global Health Innovation Fund and Bristol-Myers Squibb.